Printer Friendly

TWO NEW CORDIS ANGIOPLASTY CATHETERS GAIN U.S. MARKET RELEASE

 MIAMI, Dec. 29 /PRNewswire/ -- Cordis Corporation (NASDAQ-NMS: CORD) said today that the Food and Drug Administration has approved the U.S. market release of two new balloon angioplasty devices: the Olympix and Sleuth XT PTCA Dilatation Catheters. The company's most advanced devices to date, the new catheters are designed to treat coronary arteries occluded by the buildup of fatty deposits, or plaque, associated with atherosclerosis.
 Robert C. Strauss, president and chief executive officer, termed the approvals "a significant development in Cordis' efforts to increase its competitiveness in angioplasty. These newest devices represent a major step in addressing customer needs in the over-the-wire segment of the market, which accounts for some 55 percent of all U.S. angioplasty procedures."
 Olympix PTCA Dilatation Catheters incorporate a number of highly attractive features: Cordis' unique MaxTrax shaft technology system, inner and outer lubricious coatings, profiles so low that they rival those of even fixed-wire catheters and a 25 percent higher rated burst pressure than the company's current dilatation catheters. Combining exceptional handling, maneuverability and balloon strength, these performance features enable the devices, guided by interventional cardiologists, to track tortuous vessels and cross and dilate severely diseased, difficult-to-reach lesions.
 Sleuth XT PTCA Dilatation Catheters feature the same MaxTrax shaft system and the same 25 percent increase in balloon-rated burst pressure. The latter feature, it should be noted, aids physicians in treating highly calcified lesions.
 Like Cordis' other dilatation catheters, Olympix and Sleuth XT devices incorporate a proprietary balloon material, Duralyn. In addition to its enhanced, exceptional strength, Duralyn assures inflated balloon diameters that are predictable, accurate and consistent -- all highly desirable performance features for physicians carrying out an angioplasty procedure.
 The Olympix and Sleuth XT catheters are Cordis' third and fourth balloon devices released so far in fiscal 1993, which began July 1. FDA had earlier approved introduction of the Sleuth and the Orion Soft Tip, over-the-wire and fixed-wire dilatation catheters, respectively. The company has a number of other balloon catheters pending regulatory approval.
 Shipments of Olympix catheters to U.S. customers will begin next month with Sleuth XT catheters following shortly thereafter. For the most part, both lines of devices currently are being sold in foreign markets, where they are being increasingly well received.
 Miami-based Cordis Corporation manufactures and markets a variety of medical devices and systems for the angiographic and neuroscience markets. Shares of the company's stock are traded on the NASDAQ National Market under the symbol CORD.
 -0- 12/29/92
 /CONTACT: Chick McDowell, vice president-corporate relations and assistant secretary of Cordis Corporation, 305-824-2821/
 (CORD)


CO: Cordis Corporation ST: Florida IN: MTC SU: PDT

AW-JB -- FL001 -- 0260 12/29/92 08:56 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 29, 1992
Words:441
Previous Article:NORD SUBSIDIARY RECEIVES INITIAL FUNDING OF LOANS FROM CONSORTIUM OF INTERNATIONAL DEVELOPMENT BANKS
Next Article:INTERNATIONAL TECHNOLOGY CORP. AWARDED MATHER AFB CONTRACT
Topics:


Related Articles
SCIMED TO INTRODUCE THREE NEW PRODUCTS
CORDIS INTRODUCES PERIPHERAL RADIOLOGY PRODUCTS
CORDIS INTRODUCES PERIPHERAL RADIOLOGY PRODUCTS
SCHNEIDER'S LASER-WELDED BALLOON CATHETER APPROVED FOR MARKETING BY FDA
SCHNEIDER LAUNCHES NEW 7 FRENCH GUIDING CATHETER
FOUR CORDIS ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE
SCHNEIDER BEGINS MARKETING BALLOON CATHETER 'FREEHAND'
CORDIS INTRODUCES NEW ANGIOPLASTY CATHETER LINE
SCHNEIDER LAUNCHES THREE NEW BALLOON CATHETERS
FDA Clears Palmaz-Schatz(R) Crown Stent For Coronary Patients

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters